PrimaNova

PrimaNova Technologies, founded in 2020 with its inception in 2019, is a medical technology company focused on addressing critical unmet needs within the neurosurgery and neurocritical care sectors. Based in Shenzhen, China, with offices in Beijing and Hong Kong, the company was co-founded by Wen Ping (COO), Alan Au, and Li Mingxi. They are guided by President Sampson Lau and a board that includes Daniel Burnett. PrimaNova operates by developing a pipeline of products that leverage microsensors, signal processing, and automation to provide clinicians with enhanced precision and data-driven insights.

The company's business model centers on the research, development, and eventual sale of specialized medical equipment. A key product is the PrimaNova® Neurointensive Monitoring System, designed for patients with conditions like stroke or traumatic brain injury. This system features a catheter kit for measuring intracranial pressure (ICP) and temperature, and a monitor with a 12.1" touchscreen that displays real-time data transmitted wirelessly. A significant feature is its wireless capability, facilitating continuous monitoring for over seven days and easing patient transfers. The system aims to provide superior accuracy, with an ICP accuracy of ≤ 1mmHg, to improve patient outcomes. As of early 2024, this device has completed its NMPA clinical trial in China and is pending further regulatory approvals.

PrimaNova actively forms strategic partnerships to expand its technological capabilities. In 2023, it partnered with Panda Surgical to support the development of a handheld robotics platform for minimally invasive neurosurgery. Another 2023 collaboration with NeuroCarta focuses on a handheld cortical stimulator to improve the precision of tumor removal in brain cancer patients. The company's growth is supported by multiple financing rounds, including Series A, A1, and A2 rounds between 2020 and 2023, with investment from firms like Shanghai Healthcare Capital. These funds are directed towards product research and clinical development, positioning the company to introduce a portfolio that also includes solutions for cerebrospinal fluid (CSF) management.

Keywords: neurosurgery, medical devices, neurocritical care, intracranial pressure monitoring, ICP monitoring, neuromonitoring, CSF management, medtech, Shenzhen, neurotrauma, handheld surgical robotics, cortical stimulation, traumatic brain injury, stroke care, minimally invasive surgery, clinical development, medical sensors, signal processing, healthcare automation